CR20240552A - Anticuerpos igf1r - Google Patents

Anticuerpos igf1r

Info

Publication number
CR20240552A
CR20240552A CR20240552A CR20240552A CR20240552A CR 20240552 A CR20240552 A CR 20240552A CR 20240552 A CR20240552 A CR 20240552A CR 20240552 A CR20240552 A CR 20240552A CR 20240552 A CR20240552 A CR 20240552A
Authority
CR
Costa Rica
Prior art keywords
igf1r antibodies
antibodies
igf1r
insulin
bind
Prior art date
Application number
CR20240552A
Other languages
English (en)
Inventor
Christopher Davidson Ward
Iii Martin Jack Borrok
Original Assignee
Horizon Therapeutics Ireland Dac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Dac filed Critical Horizon Therapeutics Ireland Dac
Publication of CR20240552A publication Critical patent/CR20240552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se describen anticuerpos que se unen e inhiben la señalización a través del receptor 1 del factor de crecimiento similar a la insulina.
CR20240552A 2022-06-10 2023-06-08 Anticuerpos igf1r CR20240552A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263351077P 2022-06-10 2022-06-10
US202363500168P 2023-05-04 2023-05-04
PCT/IB2023/000335 WO2023237928A2 (en) 2022-06-10 2023-06-08 Igf1r antibodies

Publications (1)

Publication Number Publication Date
CR20240552A true CR20240552A (es) 2025-01-29

Family

ID=87561029

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240552A CR20240552A (es) 2022-06-10 2023-06-08 Anticuerpos igf1r

Country Status (17)

Country Link
US (1) US20230406942A1 (es)
EP (1) EP4536704A2 (es)
JP (1) JP2025519612A (es)
KR (1) KR20250050855A (es)
CN (1) CN119768431A (es)
AU (1) AU2023282504A1 (es)
CA (1) CA3258537A1 (es)
CL (1) CL2024003776A1 (es)
CO (1) CO2024018155A2 (es)
CR (1) CR20240552A (es)
IL (1) IL317545A (es)
JO (1) JOP20240273A1 (es)
MX (1) MX2024015238A (es)
PE (1) PE20250926A1 (es)
TW (1) TW202421661A (es)
UY (1) UY40308A (es)
WO (1) WO2023237928A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197511A1 (en) * 2023-12-13 2025-06-19 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2019173352A1 (en) * 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
WO2023122714A2 (en) * 2021-12-23 2023-06-29 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
US20250197511A1 (en) * 2023-12-13 2025-06-19 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease

Also Published As

Publication number Publication date
CO2024018155A2 (es) 2025-01-13
EP4536704A2 (en) 2025-04-16
MX2024015238A (es) 2025-01-09
IL317545A (en) 2025-02-01
US20230406942A1 (en) 2023-12-21
CN119768431A (zh) 2025-04-04
KR20250050855A (ko) 2025-04-15
AU2023282504A1 (en) 2025-01-09
WO2023237928A2 (en) 2023-12-14
PE20250926A1 (es) 2025-04-02
JOP20240273A1 (ar) 2024-12-10
WO2023237928A3 (en) 2024-02-08
TW202421661A (zh) 2024-06-01
JP2025519612A (ja) 2025-06-26
CA3258537A1 (en) 2023-12-14
UY40308A (es) 2023-12-29
CL2024003776A1 (es) 2025-06-27

Similar Documents

Publication Publication Date Title
CU24568B1 (es) Anticuerpo inhibidor de masp-3
CL2023001091A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
ES2683847T3 (es) Inmunoglobulina citotóxica
PE20161152A1 (es) Anticuerpos y metodos de uso
MX2019010206A (es) Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
FI4249515T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
CL2022001083A1 (es) El uso de un modulador de empalme para un tratamiento que retrasa la progresión de la enfermedad de huntington
CO2024018155A2 (es) Anticuerpos igf1r
PY2014556A (es) Anticuerpos que reconocen tau
MX2018012418A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
WO2019117685A3 (ko) 항-igf1r 항체 및 그 용도
CU20210039A7 (es) Anticuerpos que reconocen tau
PE20230381A1 (es) Proteina de union a rgma
MX2018013306A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
MX2025000550A (es) Conjugados anticuerpo-fármaco que se unen a la proteína 1 que contiene el dominio cub (cdcp1) y usos de los mismos
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CL2022001673A1 (es) Anticuerpos contra la integrina alfa 11 beta 1.
ZA202310247B (en) Anti il-1 receptor accessory protein antibodies
MX2022001305A (es) Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
MX2019011695A (es) Empaque para bioinsumos a base de los artropodos beneficos encarsia formosa y amitus fuscipennis.